Zydus receives USFDA approval for Prochlorperazine Maleate tablets

Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) to market Prochlorperazine Maleate tablets, USP 5 mg and 10 mg, (USRLD: Compazine).

Prochlorperazine tablets are used to treat nervous, emotional, and mental conditions (eg. schizophrenia) and non-psychotic anxiety. It is also used to control severe nausea and vomiting. The drug will be manufactured at the group's formulation manufacturing facility at Ahmedabad SEZ, India.

Prochlorperazine Maleate tablets had annual sales of USD 30 million in the United States according to IQVIA MAT June 2022.

Powered by Capital Market - Live News

 

Make smarter market moves with The Smart Investor. Daily insights on buzzing stocks and actionable information to guide your investment decisions delivered to your inbox.